ReNeuron Group Share Forecast, Price & News

GBX 117.50
0.00 (0.00 %)
(As of 06/15/2021 09:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume150,613 shs
Average Volume244,193 shs
Market Capitalization£66.82 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RENE News and Ratings via Email

Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter.

ReNeuron Group logo

About ReNeuron Group

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. ReNeuron Group plc has a research agreement with U.S. biotechnology company in the discovery and development of novel gene silencing-based therapeutics. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.60 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ReNeuron Group (LON:RENE) Frequently Asked Questions

What stocks does MarketBeat like better than ReNeuron Group?

Wall Street analysts have given ReNeuron Group a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ReNeuron Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ReNeuron Group's next earnings date?

ReNeuron Group is scheduled to release its next quarterly earnings announcement on Monday, July 19th 2021.
View our earnings forecast for ReNeuron Group

How were ReNeuron Group's earnings last quarter?

ReNeuron Group plc (LON:RENE) issued its earnings results on Monday, July, 20th. The company reported ($35.90) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($50.20) by $14.30.
View ReNeuron Group's earnings history

How has ReNeuron Group's stock price been impacted by Coronavirus?

ReNeuron Group's stock was trading at GBX 106 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RENE shares have increased by 10.8% and is now trading at GBX 117.50.
View which stocks have been most impacted by COVID-19

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the following people:
  • Mr. Olav Hellebo, CEO & Director (Age 56, Pay $397k)
  • Mr. Michael E. Hunt A.C.A., BSc, ACA, CFO, Company Sec. & Exec. Director (Age 58, Pay $247k)
  • Ms. Suzanne Hancock, Head of Operations
  • Mr. Shaun Stapleton, Head of Regulatory Affairs and VP of Regulatory Affairs & Pharmacovigilance
  • Dr. Richard L. Beckman, Chief Medical Officer

Who are some of ReNeuron Group's key competitors?

What other stocks do shareholders of ReNeuron Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include 10094 (IRD.TO) (IRD), Sareum (SAR), ValiRx (VAL), IOG (IOG), Dignity (DTY), Tri-Star Resources plc (TSTR.L) (TSTR), Sirius Minerals (SXX), Collagen Solutions plc (COS.L) (COS), RenovaCare (RCAR) and ReNeuron Group (RNUGF).

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE."

How do I buy shares of ReNeuron Group?

Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is ReNeuron Group's stock price today?

One share of RENE stock can currently be purchased for approximately GBX 117.50.

How much money does ReNeuron Group make?

ReNeuron Group has a market capitalization of £66.82 million and generates £112,000.00 in revenue each year.

How many employees does ReNeuron Group have?

ReNeuron Group employs 62 workers across the globe.

What is ReNeuron Group's official website?

The official website for ReNeuron Group is www.reneuron.com.

Where are ReNeuron Group's headquarters?

ReNeuron Group is headquartered at Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400.

This page was last updated on 6/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.